Journals
Cancer Cell Research

Journal Description

Cancer Cell Research Vol. 11 NO.42 2024

Issue Cover
get_app
Article
Progress of network pharmacology-based research on Chinese medicine compounds for hyperuricemia
by
Zhongyu Wang
,
Hongzong Si
.
Cancercellresearch 2024, 11(42), 943-951; https://doi.org/10.54762/ccr2024.943-952 (registering DOI) - 21 Mar. 2024
Abstract
: Hyperuricemia represents a prevalent metabolic condition characterized by dysregulated purine metabolism, culminating in excessive uric acid production. [...] Read more.
: Hyperuricemia represents a prevalent metabolic condition characterized by dysregulated purine metabolism, culminating in excessive uric acid production. This pathology may progress to more serious complications, including gout. The United Nations has recognized hyperuricemia as one of the twenty major chronic diseases in the 21st century, reflecting its global impact. In China, the incidence of this disease has been rising, yet long-term treatment strategies and drug development continue to face challenges. Traditional Chinese Medicine (TCM) offers an alternative approach to managing hyperuricemia, boasting characteristics such as holistic treatment principles, adaptability, and reduced side effects compared to conventional Western therapies. Despite these benefits, the precise mechanisms underlying the efficacy of certain TCM compound treatments remain enigmatic. In the current clinical landscape, network pharmacology has emerged as a powerful tool to dissect the intricate interactions between drugs, diseases, and molecular targets. It provides a systems-level perspective, elucidating the "multi-component, multi-target, and multipathway" synergistic relationships inherent in TCM compound treatments. This integrative approach holds promise for enhancing our understanding of TCM's therapeutic effects and could pave the way for more refined and personalized treatment strategies in the management of hyperuricemia. The current studies on the use of network pharmacology in the treatment of hyperuricemia by using Chinese medicine compounding, elucidated the active ingredients, targets, biological processes and pathway analysis of the single drugs in Chinese medicine compounding, and explored the prospect of network pharmacology research with a view to better developing the application of Chinese medicine compounding in clinical practice. Full article
(This article belongs to the Section Cancer cell Research)
get_app
Article
A review of the literature on radiation recall phenomena in induced by COVID-19 infection or vaccination in cancer patients
by
Lingling Feng
,
Shosei Shimizu
,
Feiyan Deng
.
Cancercellresearch 2024, 11(42), x-x; -1 Jun. 2023
Abstract
: Objective: Radiation recall (RR) is a known complication of coronavirus disease 2019 (COVID-19) and can cause severe disease. The aim of the present review was to provide additional insights into this phenomenon. [...] Read more.
: Objective: Radiation recall (RR) is a known complication of coronavirus disease 2019 (COVID-19) and can cause severe disease. The aim of the present review was to provide additional insights into this phenomenon.Methods: The PubMed, Embase, Scopus, and Web of Science databases were searched until February 1, 2023, using the keywords radiation therapy, recall, and COVID-19, limiting the search to human studies and publications in English. The studies included case reports of patients who developed RR symptoms initiated by either COVID-19 infection or vaccination.Results: Twelve studies and 15 case reports were identified. RR reactions involved the skin, lungs, and laryngeal mucosa, of which radiation recall dermatitis (RRD) was the most frequent. Local symptoms were largely self-limiting, with only a few cases requiring anti-inflammatory drugs, and one patient needing a tissue transplant. Patients with radiation recall pneumonitis (RRP) resulting from infection experienced a drop in oxygen partial pressure to varying degrees. Symptoms after vaccination were mild. Radiation recall mucositis (RRM) in the laryngeal mucosa could pose a risk of death. Conclusions: In the era of COVID-19, RR is a complex toxicity that can occur after a wide range of radiotherapy doses. Most commonly, it presents in the skin. RRD symptoms were largely self-limiting, while RRP due to infection and RRM may be potentially life-threatening. Although there are relatively few reports of RR, it has been reported worldwide and various acute phase reactions to radiotherapy such as dermatitis, pneumonitis, and mucositis have been described. It has also been reported not only with viral infections but also with various vaccines.These reports are likely to be the tip of the iceberg, as RR is difficult to detect unless each patient and physician are aware of them. More attention and follow-up are required. These reports may also be a reference for infectious diseases in the future. Full article
(This article belongs to the Section cancercellresearch)
Back to TopTop